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have a key homologous recombination role in VlsE variation
within B. burgdorferi [4]. RecA mutant strains of B. burgdorferi
were still able to undergo mosaic VlsE lipoprotein variation,
so RecA would appear not to have a role in the recombina-
tion events utilized for antigenic variation in Borrelia, in con-
trast to other organisms, such as Neisseria gonorrhoeae [5].
Furthermore, possession of non-functional RecA has been
shown not to have any deleterious effects on the infectious-
ness of B. burgdorferi. This is in contrast to the lethality of
RecA mutations hypothesized by others [6]. However, this
strain showed a loss in ability to cause joint infections [4].
These ﬁndings suggest that loss of RecA may not affect the
viability of the closely related relapsing fever spirochaetes,
but could account for differences in clinical consequences.
Indeed, clinical differences are seen between these infections,
with B. recurrentis resulting in signiﬁcant jaundice, petechiae,
epistaxis and major organ involvement (central nervous
system and cardiac), and B. duttonii being associated with
pregnancy complications and high perinatal mortality [7].
The obvious difference between these two spirochaetes is
their ability to be either tick-borne or louse-borne, resulting
in either local endemic or epidemic disease, respectively. It
is unlikely that RecA is not necessary among louse-borne
pathogens, as RecA remains functional in Rickettsia prowazekii,
another louse-borne pathogen whose genome is also subject
to degradation as compared with non-louse-borne counter-
parts [8]. Whether the truncation of RecA within B. recurren-
tis plays a role in the differing clinical presentations or
vectorial capabilities of these spirochaetes remains to be
determined. What is apparent is that samples from louse-
borne relapsing fever patients showed the same ‘signature’
SNPs, differentiating them from B. duttonii, including the pre-
mature stop codon, thus suggesting a clonal ancestry.
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Abstract
Thirty-ﬁve multidrug-resistant Acinetobacter baumannii strains,
representative of 28 outbreaks involving 484 patients from 20
hospitals in Greece, Italy, Lebanon and Turkey from 1999 to
2009, were analysed by multilocus sequence typing. Sequence
type (ST)2, ST1, ST25, ST78 and ST20 caused 12, four, three,
three and two outbreaks involving 227, 93, 62, 62 and 31
patients, respectively. The genes blaoxa-58, blaoxa-23 and blaoxa-72
were found in 27, two and one carbapenem-resistant strain,
respectively. In conclusion, A. baumannii outbreaks were caused
by the spread of a few strains.
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Acinetobacter baumannii epidemics have been recently
described in Europe, and are caused worldwide by a limited
number of genotypic clusters of strains [1–14]. Major A. bau-
mannii outbreak clones were initially named European clo-
nes I to III, but are now regarded as international [14].
Multilocus sequence typing (MLST) is the standard method
for deﬁning the clonal structure of bacterial species, and has
deﬁned clones 1–3 as clonal complexes (CCs) 1–3 [14–16].
The aims of the present study were: (i) using MLST, to
deﬁne the genetic identity of A. baumannii strains associated
with outbreaks in Mediterranean hospitals; (ii) to compare
MLST data with those obtained using pulsed-ﬁeld gel electro-
phoresis (PFGE) and trilocus sequence-based typing (3LST)
[17]; and (iii) to identify the genes for carbapenem-hydroly-
sing b-lactamases involved in these outbreaks.
Thirty-ﬁve A. baumannii strains isolated during 28 out-
breaks that occurred in 20 hospitals in Greece, Italy, Leba-
non and Turkey from 1999 to 2009 were included in the
study. Nearly all strains were representative of cross-trans-
TABLE 1. Epidemiological, phenotypic and genotypic data of the Acinetobacter baumannii isolates included in the study










MIC CHDL MBLcpn60 fusA gltA pyrG recA rpIB rpoB
700 F-Naples/IT 1999 81 A 1 1 1 1 5 1 1 1 2 0.5
3891 Thessaloniki/GR 2000 3 B 1 1 1 1 5 1 1 1 2 16 OXA-58
3886 Athens/GR 2005 4 B 1 1 1 1 5 1 1 1 2 16 OXA-58
3887 Serres/GR 2006 5 C 1 1 1 1 5 1 1 1 2 32 OXA-58 VIM-4
2979 Agrigento/IT 2002 14 D 3 1 1 1 5 1 1 20 2 0.5
3130 SG-Beirut/LB 2004 17 E 3 1 1 1 5 1 1 20 2 16 OXA-58
2105 F-Naples/IT 2002 43 F 2 2 2 2 2 2 2 2 1 16 OXA-58
2638 M-Naples/IT 2003 42 F 2 2 2 2 2 2 2 2 1 16 OXA-58
3892 Thessaloniki/GR 2003 23 F 2 2 2 2 2 2 2 2 1 16 OXA-58
3893 Larissa/GR 2004 48 F 2 2 2 2 2 2 2 2 1 16 OXA-58
3894 Serres/GR 2006 19 F 2 2 2 2 2 2 2 2 1 32 OXA-58 VIM-1
4245 Pozzuoli/IT 2009 4 F 2 2 2 2 2 2 2 2 1 16 OXA-58
2735 M-Naples/IT 2004 2 F1 2 2 2 2 2 2 2 2 1 64 OXA-58
3858 Catania/IT 2004 27 F2 2 2 2 2 2 2 2 2 1 2
3889 Athens/GR 2005 4 G 2 2 2 2 2 2 2 2 1 16 OXA-58
4026 SJ-Beirut/LB 2007 5 H 2 2 2 2 2 2 2 2 1 16 OXA-58
4030 SG-Beirut/LB 2006 6 I 2 2 2 2 2 2 2 2 1 16 OXA-58
4009 Genoa/IT 2007 4 J 2 2 2 2 2 2 2 2 1 32 OXA-23
3237 SG-Beirut/LB 2004 1 K 3 3 2 2 3 1 3 3 3 1
4025 SG-Beirut/LB 2005 3 K 3 3 2 2 3 1 3 3 3 16 OXA-58
3890 Thessaloniki/GR 2003 12 L 3 3 2 4 7 2 4 25 4 16 OXA-58
3865 Kocaeli/TK 2005 47 M 3 3 2 4 7 2 4 25 4 64 OXA-23
OXA-58
4190 M-Naples/IT 2009 3 N 3 3 2 4 7 2 4 25 4 64 OXA-72
3909 M-Naples/IT 2007 55 O 25 3 6 2 28 1 29 78 6 16 OXA-58
3696 CT-Naples 2007 4 O 25 3 6 2 28 1 29 78 6 16 OXA-58
3933 CA-Naples/IT 2007 1 O 25 3 6 2 28 1 29 78 6 2
4175 CA-Naples/IT 2009 2 O 25 3 6 2 28 1 29 78 6 16 OXA-58
3868 Izmir/TK 2003 2 P 6 6 8 2 3 5 4 15 5 16 OXA-58
3869 Istanbul/TK 2003 1 P 6 6 8 2 3 5 4 15 5 16 OXA-58
3871 Istanbul/TK 2003 1 P1 6 6 8 2 3 5 30 84 5 16 OXA-58
3872 Izmir/TK 2003 1 P1 6 6 8 2 3 5 30 84 5 16 OXA-58
3875 Trabzon/TK 2003 1 P1 6 6 8 2 3 5 30 84 5 16 OXA-58
2978 Agrigento/IT 2001 3 Q 28 3 2 1 4 4 4 82 1
2977 Agrigento/IT 2001 1 Q 28 3 2 1 4 4 4 82 16 OXA-58
3866 Kayseri/TK 2003 2 R 26 4 2 2 9 1 4 83 16 OXA-58
CA-Naples, Cardarelli Hospital, Naples; CT-Naples, Cotugno Hospital, Naples; F-Naples, Federico II University Hospital, Naples; M-Naples, Monaldi Hospital, Naples; SG-Bei-
rut, Saint Gorge Hospital, Beirut; SJ-Beirut, Saint Joseph Hospital, Beirut; GR, Greece; IT, Italy; LB, Lebanon; TK, Turkey; CHDL, class D carbapenem-hydrolysing oxacillinase;
IMP, imipenem; MBL, class B metallo-b-lactamase; MLST, multilocus sequence typing; PFGE, pulsed-ﬁeld gel electrophoresis; ST, sequence type; 3LST, trilocus sequence-based
typing.
aNumber of patients from whom an isolate with each particular PFGE type was detected. Strain 3237 from Beirut, strain 3933 from Naples, strain 2977 from Agrigento and
strains 3869, 3871, 3872 and 3875 from Turkey were single isolates in different hospitals.
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mission episodes, and were isolated with identical PFGE
types from more than two patients of the same or different
institutions (Table 1). Antimicrobial susceptibilities were
determined by a reference microdilution method [18].
Although A. baumannii strains were not a priori selected
because of a multidrug resistance phenotype, all of the
strains were resistant to more than two of ﬁve antimicrobial
classes and were considered to be multidrug-resistant [1]; 29
of 35 strains exhibited an imipenem MIC ‡16 mg/L and were
considered to be carbapenem-resistant (Table 1). PFGE anal-
ysis and interpretation of PFGE proﬁles were performed as
reported previously [6]. Eighteen PFGE types (A–R) and
three PFGE subtypes (F1, F2 and P) were identiﬁed
(Table 1).
MLST analysis was performed as previously described [14]
(http://www.pasteur.fr/mlst). Only ten different sequence
types (STs) were found. Strains with PFGE proﬁles A–C, D
and E, F–J and L–N were assigned to ST1, ST20, ST2 and
ST25, respectively; strains with PFGE proﬁles K, O, P, P1, Q
and R were assigned to ST3, ST78, ST15, ST84, ST82 and
ST83, respectively. Interestingly, more than six band differ-
ences were found among PFGE proﬁles A, B and C, among
PFGE proﬁles F, G, H, I and J, and among PFGE proﬁles L, M
and N, respectively, showing that international STs ST1, ST2
and ST25 represent heterogenous genotypic entities. ST2
predominated, being identiﬁed in 12 strains from 11 hospitals
in Greece, Italy and Lebanon (Table 1 and Fig. 1). Together,
these 12 strains represented 12 clusters that involved 227
(46.2% of the total) infected patients. The other most fre-
quently assigned STs were ST1, ST20, ST25 and ST78. They
were identiﬁed in four, two, three and four strains, respec-
tively, representing 93 (18.9%), 31 (6.3%), 62 (12.6%) and 62
(12.6%) patients. The results are in accordance with previous
reports showing that many hospital A. baumannii strains cir-
culating in Europe and elsewhere belonged to international
clones CC1 and CC2, respectively [1,3,4,7,12,14]. Also, as in
the Czech Republic [7], a shift towards ST2 (international
clone II) was observed in Greece, Italy and Lebanon. Nota-
bly, strains assigned to ST2 and PFGE proﬁle F were
observed to progressively overtake, numerically, those
assigned to ST1. Indeed, between 1999 and 2006, ST1 repre-
sented four strains (93 patients, 23% of the total over this
period), whereas between 2002 and 2009, ST2 represented
12 strains (227 patients, 56% of the total over this period;
Table 1 and Fig. 1). Moreover, strains assigned to ST2 with
PFGE proﬁle F were isolated in three Italian hospitals and
FIG. 1. Geographical distribution and genotypic characterization of Acinetobacter baumannii strains included in the study. Black dots indicate the
location of hospitals in which A. baumannii strains were isolated. Cities are indicated by the following letters: G, Genoa; N, Naples; AG, Agrigen-
to; C, Catania; L, Larissa; T, Thessaloniki; AT, Athens; S, Serres; IS, Istanbul; IZ, Izmir; KO, Kocaeli; TR, Trabzon; B, Beirut. Coloured pie charts
indicate the prevalence of A. baumannii isolates assigned to different sequence types (STs) in each country. The size of circles is related to the
number of patients per countries as indicated. Carbapenem-hydrolysing enzymes isolated in each city are also indicated.
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three Greek hospitals (Table 1), thus suggesting that this
clone might have encountered favourable conditions for
spread within the same city or between different countries,
as described for other A. baumannii epidemics [1,2,5,6]. Our
data also demonstrate the diffusion of strains assigned to
ST25 in Greece, Italy and Turkey, of those assigned to ST78
in Italy, and of those assigned to ST15 and ST84 in Turkey
(Table 1 and Fig. 1).
eBURST analysis [19] of the ten STs as compared with
the 82 proﬁles of the database showed that ST20 and ST1
are single-locus variants and belong to CC1 [14]. ST84
formed a novel CC with ST15, as these two STs differ by
a single allelic mismatch. ST82 was placed in CC10 [14] as
a single-locus variant of ST10. All other STs were single-
tons, i.e. differed by at least two genes from all other pro-
ﬁles. A. baumannii CCs can be regarded as clones
[14,19,20]. Typing results generated by 3LST [17] were
concordant with MLST data (Table 1). No novel 3LST
group was assigned to strains 2977, 2978 and 3866,
because they were microepidemic strains [8]. Overall, the
present data show that A. baumannii strains circulating
between 1999 and 2009 represent a highly structured pop-
ulation. The MLST scheme adopted herein [14] differs from
the MLST scheme used in previous publications [13,15,16];
correspondence can be established using genome sequences
or reference strains.
In accordance with previous ﬁndings [1,2,9,10,12], a
class D carbapenem-hydrolysing oxacillinase was found in all
29 carbapenem-resistant strains by PCR and DNA sequence
experiments, performed as reported previously [6]. The
blaOXA-58 gene was identiﬁed in 27 strains assigned to 18 dis-
tinct PFGE proﬁles and STs. The blaOXA-23 gene was identi-
ﬁed in an ST2 strain from Genoa, Italy, and in an ST25 strain
from Kocaeli, Turkey; the blaOXA-72 gene was found in an
ST25 strain from Naples, Italy. The metallo-b-lactamase-
encoding genes blaVIM-1 and blaVIM-4 were detected in ST2
and ST1 strains isolated in Greece (Table 1 and Fig. 1). No
acquired class D carbapenem-hydrolysing oxacillinasess or
metallo-b-lactamasess were identiﬁed in the six carbapenem-
susceptible strains (Table 1). In accordance with our data,
the genes blaOXA-23, blaOXA-24 and blaOXA-58 were found in a
few distinct clusters deﬁned by other typing methods, some
of which correspond to international clones I, II and III
[7,10,12,13].
In conclusion, A. baumannii outbreaks in four Mediterra-
nean countries were caused by the spread of strains belong-
ing to few genotypes, in particular ST2 and, to a lesser
extent, ST1, ST25 and ST78, probably favoured by the
blaOXA-58, blaOXA-23 and blaOXA-72 genes. The MLST scheme
utilized herein represents a useful standardized typing
method for identifying important A. baumannii clones and
tracking their geographical expansion.
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Abstract
We describe eight human cases of Bordetella bronchiseptica infec-
tion and colonization over a 15-year period. Amongst the eight
patients, seven had signiﬁcant underlying disease. Cat exposure
was documented in three cases. Symptoms ranged from asymp-
tomatic carriage to severe pneumonia. We could not identify a
homogeneous pattern of clinical disease among symptomatic
patients. Although B. bronchiseptica infection remains a rare clini-
cal condition among humans, it should be considered as poten-
tially pathogenic when found in airways of immunocompromised
patients.
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Bordetella spp. are aerobic coccobacilli known to be present
in the upper respiratory tract of many animals [1]. B. bron-
chiseptica infections are uncommon in humans [2]. The
literature on this subject is subsequently poor. Two compre-
hensive reviews have been published in the last two decades.
The ﬁrst included 25 cases from 1911 to 1990 [1]. However,
the presence of B. bronchiseptica was microbiologically con-
ﬁrmed in only ten patients. The other study, published in
1995, included 52 patients but no details were provided
about the microbiological identiﬁcation of B. bronchiseptica
[3]. Another study published in 2005 focused on the patho-
genesis but gave little information on human infections [4].
Recently, several case reports addressed the problem in cys-
tic ﬁbrosis patients [5], HIV patients [2,6] or children with
lung transplants [7]. Facing this lack of recent information,
we decided to review all cases detected at our institution
from 1993 to 2008.
The present study was undertaken at the Geneva Univer-
sity Hospitals, a 2220-bed tertiary care centre. We per-
formed a retrospective case review approved by the
institutional ethics review board and based on computerized
laboratory log ﬁles, examining the pattern of disease caused
by B. bronchiseptica, addressing underlying conditions and
exposures, and examining antimicrobial treatment in relation
to patient outcome. To avoid misclassiﬁcation bias, we
included only patients with veriﬁed B. bronchiseptica isolates
because automated identiﬁcation systems can lead to misclas-
siﬁcation as Acinetobacter spp. or other nonfermentative
Gram-negative rods. Most cases were ﬁrst identiﬁed by API
20NE gallery or VITEK2 (bioMerieux SA, Marcy-l’Etoile,
France) phenotypic identiﬁcation systems, and then sup-
ported by a positive oxidase reaction. All available stored
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